Krystal Biotech (KRYS) Total Current Liabilities (2016 - 2026)

Krystal Biotech's Total Current Liabilities history runs 11 years deep, the most recent figure standing at $107.8 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 35.62% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $107.8 million (up 35.62% YoY), while the FY2025 annual figure was $102.9 million, up 0.93% from the prior year.
• Total Current Liabilities came in at $107.8 million for Q1 2026 at Krystal Biotech, up from $102.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $107.8 million in Q1 2026 to a low of $23.9 million in Q2 2023.
• A 5-year average of $61.8 million and a median of $60.4 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 560.95% in 2022 and slumped 41.96% in 2023, its largest moves.
• Krystal Biotech's Total Current Liabilities stood at $28.8 million in 2022, then climbed by 14.72% to $33.1 million in 2023, then soared by 208.2% to $102.0 million in 2024, then grew by 0.93% to $102.9 million in 2025, then increased by 4.72% to $107.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $107.8 million, $102.9 million, and $91.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison